Pulmonary Arterial Hypertension

Category icon
Treating Acute Heart Failure with Chronic Obstructive Pulmonary Disease

Jelena Celutkiene, Mindaugas Balčiūnas, Denis Kablučko, et al

Category icon
Pulmonary Hypertension in Heart Failure Patients

Sriram D Rao, Srinath Adusumalli, Jeremy A Mazurek,

Category icon
PVI Versus Amiodarone in AF and CHF

Michela Faggioni, Domenico G Della Rocca, Sanghamitra Mohanty, et al

Category icon
Treating Acute Heart Failure with Chronic Obstructive Pulmonary Disease

Jelena Celutkiene, Mindaugas Balčiūnas, Denis Kablučko, et al

Category icon
Pulmonary Hypertension in Heart Failure Patients

Sriram D Rao, Srinath Adusumalli, Jeremy A Mazurek,

Category icon
PVI Versus Amiodarone in AF and CHF

Michela Faggioni, Domenico G Della Rocca, Sanghamitra Mohanty, et al

About

Pulmonary arterial hypertension (PAH) is a chronic and life-threatening disease characterised by progressive vascular remodelling that leads to increased pulmonary vascular resistance, right ventricular heart failure and death.

PAH is defined by >25 mmHg increase in pulmonary arterial blood pressure and a pulmonary capillary wedge pressure of 15 mmHg. If left untreated, PAH is fatal; it has a survival rate of just 34% after 5 years. Current therapies include stimulating the nitric oxide (NO)–soluble guanylate cyclase (sGC)–cyclic guanosine monophosphate (cGMP) axis, improving the prostacyclin pathway or inhibiting the endothelin pathway.

Related Articles

Articles

Article icon
Treating Acute Heart Failure with Chronic Obstructive Pulmonary Disease

Jelena Celutkiene, Mindaugas Balčiūnas, Denis Kablučko,

Citation: Cardiac Failure Review 3(1):56–61.

Pulmonary Hypertension in Heart Failure Patients

Sriram D Rao, Srinath Adusumalli, Jeremy A Mazurek,

Published:

Citation: Cardiac Failure Review 2020;6:e05.

PVI Versus Amiodarone in AF and CHF

Michela Faggioni, Domenico G Della Rocca, Sanghamitra Mohanty,

Published:

Citation: Cardiac Failure Review 2020;6:e04.